A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Abstract Text:

Thomas Owley,Jeff Salt,Stephen Guter,Adam Grieve,Laura Walton,Nelson Ayuyao,Bennett L Leventhal,Edwin H Cook,

BACKGROUND: This pilot study examined the effectiveness of memantine hydrochloride in improving cognitive functioning and behavioral symptoms in children with pervasive developmental disorders (PDDs). METHOD: Subjects aged 3-12 years inclusive were enrolled in this 8-week, open-label study. Expressive and receptive language, nonverbal IQ, and nonverbal memory measures were administered at baseline and after 8 weeks of treatment with 0.4 mg/kg of memantine hydrochloride. Throughout the study, the Aberrant Behavior Checklist (ABC) was sent in weekly by parents as a measure of behavioral change. RESULTS: Twelve of 14 subjects completed the study. Significant improvement from baseline was noted on the memory test (Children's Memory Scale Dot Learning Subtest). There were no significant differences from baseline on measures of expressive or receptive language or nonverbal IQ. There were significant improvements on a number of ABC subscales, including hyperactivity, lethargy, and irritability. There were no overall significant statistical differences from baseline on the Clinical Global Improvement-Severity (CGI-S) scale. On the Clinical Global Improvement-Improvement (CGI-I), 4 of 14 subjects showed minimal improvement, and none was deemed "much-improved" or "very much improved." CONCLUSIONS: This small, prospective, open-label study suggests that memantine may be useful in the treatment of memory functioning and some behavioral symptoms in PDDs. The investigators did not see the same degree of change as endorsed by caretakers. Controlled studies are needed to substantiate and clarify these preliminary findings.

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Publishing Authors By Initials

T Owley,J Salt,S Guter,A Grieve,L Walton,N Ayuyao,BL Leventhal,EH Cook,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of child and adolescent psychopharmacology

VOLUME: 16

Page Numbers: 517-24

Journal Abbreviation:

ISSN: 1044-5463

DAY: 3

MONTH: Oct

YEAR: 2006

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9105358

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: psychology

Chemical & Substance for Abstract: A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Information

Substance Name: Glutamic Acid

Registry Number: 56-86-0

Grant and Affiliation Information for A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

AFFILIATION: University of Illinois at Chicago, Department of Psychiatry, Institute for Juvenile Research, Chicago, Illinois 60608, USA. towley@psych.uic.edu

Country: United States

AGENCY: United States NICHD

GRANT: U19 HD35482

ACRONYM: HD

MEDLINETA: J Child Adolesc Psychopharmaco

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders Related Publications

• 449.
• 5-HTTLPR Genotype-Specific Phenotype in Children and Adolescents With Autism.
• A proposed proton shuttle mechanism for saccharopine dehydrogenase from Saccharomyces cerevisiae.
• A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.
• An intracrine view of angiogenesis.
• Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents.
• Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism.
• Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression.
• Characterization and in vitro degradation of salicylate-derived poly(anhydride-ester microspheres).
• Chronic glaucoma case finding and treatment in rural Africa: some questions and answers.
• Complete kinetic mechanism of homoisocitrate dehydrogenase from Saccharomyces cerevisiae.
• Conformational analysis of the cis- and trans-adducts of the Pictet - Spengler reaction. Evidence for the structural basis for the C(1) - N(2) scission process in the cis- to trans-isomerization.
• Differential regulation of lipopolysaccharide and Gram-positive bacteria induced cytokine and chemokine production in splenocytes by Galphai proteins.
• Effect of Medicaid Managed Care on racial disparities in health care access.
• First enantiospecific total synthesis of the important biogenetic intermediates, (+)-polyneuridine and (+)-polyneuridine aldehyde, as well as 16-epi-vellosimine and macusine A.
• Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat.
• How to improve the outcome of cataract surgery.
• ITGB3 shows genetic and expression interaction with SLC6A4.
• Improving point predictions of random effects for subjects at high risk.
• Imputation strategies for blood pressure data nonignorably missing due to medication use.
• Monitoring cataract surgical outcomes: 'hand written' registration method.
• Oxidation artifacts in the electrospray mass spectrometry of Abeta Peptide.
• Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082).
• Preventing alcohol-exposed pregnancies.
• Remarkably mild and efficient intramolecular Friedel-Crafts cyclization catalyzed by In(III).
• The effects of dietary protein on age and weight at the onset of puberty in Brown Swiss and Zebu heifers in the tropics.
• The molecular mechanisms responsible for resistance in plant-pathogen interactions of the gene-for-gene type function more broadly than previously imagined.
• Tremor/ataxia syndrome and fragile X premutation: diagnostic caveats.
• Walking stride variability on different walking surfaces: 849: june 1 2:00 PM - 2:15 PM.
• rasiRNAs, DNA damage, and embryonic axis specification.